ADHD Medication Titration in the UK: What to Expect

The appointment you waited months — possibly years — for lasts under an hour, and somewhere in the middle of it someone says the word titration. You nod. You go home. And then it lands: you have no idea what happens next, how long it takes, who prescribes what, or what "we'll review you" actually means in practice.

This is a map of that process, written for people in the UK. It is deliberately not a schedule and not a dosing guide — there is no honest version of either that can be written by anyone who has not examined you. What we can do is describe the shape of the thing, explain why it is built the way it is, and hand you a set of questions that make your next appointment more useful than your last one.

What does "titration" actually mean?

Titration is the process of finding the smallest amount of a medicine that gives you the most benefit with the fewest unwanted effects — by starting low, adjusting in steps, and reviewing between each step. It is a search, not a single decision, and it is carried out by a prescriber who can see your full health picture.

The word borrows from chemistry, where you add a reagent drop by drop until a solution changes colour. The clinical version is less tidy, because the "colour change" is you: your concentration, your sleep, your appetite, your heart rate, your mood, your ability to actually finish the thing you sat down to do. Every one of those signals moves for reasons that have nothing to do with medication, which is precisely why titration takes time and repeated review rather than one clever calculation.

Two things follow from that, and they matter more than any number. First, nothing in this article — or any article — can tell you what to take or when. Second, the fact that it is a search means an unsuccessful first attempt is a normal step in the process, not a verdict on you.

Why is it a search rather than one correct prescription?

Because the average result across thousands of trial participants tells you remarkably little about what will happen to one specific person. Medication for ADHD produces some of the largest effect sizes in psychiatry at population level: in the reference network meta-analysis of 133 double-blind randomised trials covering 14,346 children and adolescents and 10,296 adults, clinician-rated symptoms improved with a standardised mean difference of −0.79 for amphetamines and −0.49 for methylphenidate in adults, and −1.02 and −0.78 respectively in children and adolescents (Cortese et al., 2018).

Those are genuinely impressive figures, and they are also averages of averages. They are not a league table for you to act on — first-line choice differs by country and by individual, and individual response varies enormously around those means. Read them as "this class of treatment does something real for a lot of people", not as "this drug is the best one".

The same analysis contains the reason titration exists at all: efficacy and tolerability point in opposite directions. Every active medication studied had worse tolerability than placebo, measured as dropouts due to adverse effects — in adults, odds ratios of 3.26 for amphetamines, 2.39 for methylphenidate and 2.33 for atomoxetine (Cortese et al., 2018). The medicine with the largest average benefit is also, frequently, the one people stop taking. There is no shortcut through that trade-off. Titration is the shortcut: a structured way of finding where, for you, benefit and burden sit in a liveable relationship.

What gets checked along the way, and why?

Physical measurements — and they are not bureaucracy. The NICE guideline for ADHD sets out baseline checks before medication starts and ongoing monitoring during treatment, including pulse, blood pressure, height and weight, alongside review of mental health and any other conditions (NICE, 2018, updated 2019). Different medicines and different circumstances change how closely and how often, which is a conversation for your prescriber rather than a rule we can print.

The reason those particular numbers get written down is visible in the research. A network meta-analysis of 102 randomised trials covering 13,315 children and adolescents and 9,387 adults found small but consistent short-term cardiovascular movements: in adults, methylphenidate raised systolic blood pressure by about 1.66 mmHg, diastolic by 1.60 mmHg and pulse by 4.37 beats per minute (Farhat et al., 2025). Small — but worth watching, especially over years. A Swedish nested case-control study of 278,027 people with ADHD found that longer cumulative medication use was associated with higher odds of hypertension (adjusted odds ratio 1.80 beyond five years of use), while finding no significant association with arrhythmias, heart failure or ischaemic heart disease (Zhang et al., 2024). It is observational, so it cannot prove cause — but it explains exactly why a blood pressure cuff appears at every review.

Here is the detail that reframes the whole thing: not all ADHD medication moves those numbers in the same direction. In the same analysis, guanfacine lowered blood pressure and pulse in both age groups — in adults, systolic pressure fell by about 10.1 mmHg (Farhat et al., 2025). "ADHD medication" is not one pharmacological object with one physiological signature, which is another reason the monitoring is individual rather than generic.

Alongside the physical measurements, expect to be asked about the harder-to-quantify things: sleep, appetite, mood, and whether the difficulties that brought you in have actually shifted. Appetite is not a trivial question — in children, long-term methylphenidate exposure has been associated with small but statistically significant reductions in height and weight Z-scores, with the authors judging the effect sizes small and of possibly minimal clinical impact (Carucci et al., 2021). That is paediatric evidence and should not be stretched to adults, but it is why growth charts appear in children's ADHD clinics.

How long does titration take?

Longer than most people expect, and honestly: it varies enough that any specific figure would be a fiction. What we can be precise about is why it varies, which turns out to be more useful than a number.

Three things set the pace. Each adjustment needs a period of real life afterwards before anyone can judge it, so the steps cannot be stacked back to back. Different medicines declare themselves on very different timescales — some act the same day, others build over weeks — so "is this working?" is a question with a different answer date depending on what you have been prescribed. And appointment availability is a real constraint in a system under strain, which is nobody's clinical decision but shapes everyone's calendar.

The practical consequence is worth saying plainly, because it is the expectation most likely to be set wrong: the first medicine you try may not be the one you stay on, and that is a normal outcome of a search rather than a failure of yours. Stopping early is extremely common — an observational study of dispensing data across eight countries found early discontinuation common everywhere, with persistence lowest in adolescents and young adults (Brikell et al., 2024). In a systematic review of adherence, adverse effects were the most-cited reason for stopping, ahead of lack of symptom control, dosing inconvenience and stigma, and that held across age groups, medication classes and regions (Gajria et al., 2014).

Read that as an argument for reporting side effects rather than enduring them quietly. A prescriber who does not know something is happening cannot adjust for it — and "I put up with it for six weeks and then stopped taking it" is the outcome the whole titration process is designed to prevent.

What is a shared-care agreement, and why does it keep coming up?

A shared-care agreement is a written arrangement in which a specialist service starts and stabilises your medication, and your GP practice then takes over routine prescribing and monitoring, with defined responsibilities on each side. UK guidance points that way: after titration and dose stabilisation, ongoing prescribing and monitoring is expected to sit with primary care under such an arrangement (NICE, 2018, updated 2019).

The complication is that in practice this is not automatic. A national survey across England gathered data from commissioners, health professionals and people with lived experience about what actually supports pharmacological treatment of adult ADHD in primary care, precisely because the gap between the recommended model and the delivered one is well recognised (Price et al., 2024). Individual practices can and do decline shared care, for reasons that usually have more to do with capacity, funding and confidence than with any view of you.

So the single most useful thing you can do early is ask a boring administrative question before it becomes an urgent one: once I am stable, who prescribes — and is shared care agreed with my GP practice? Finding out at the start is inconvenient. Finding out when your specialist discharges you is considerably worse.

Where do Right to Choose and the waiting list fit in?

If you are in England and your GP agrees that a referral is clinically appropriate, you generally have a legal right to choose which NHS-commissioned provider that referral goes to, including for mental health services — the arrangement usually called Right to Choose (NHS England, patient choice guidance). Exclusions apply, it does not cover urgent or crisis care, and it does not apply if you are already receiving care for the same condition through another elective referral. Arrangements differ elsewhere in the UK, so check what applies where you live.

Now the honest part. Exercising that right does not create clinical capacity; it moves you between queues. The independent ADHD Taskforce commissioned to look at ADHD care in England reported services under significant pressure, with demand for assessment far outstripping what the system currently delivers (NHS England, 2025), and several popular Right to Choose providers now carry substantial waits of their own. A diagnosis obtained through one route also does not guarantee that your local practice will take on shared-care prescribing afterwards — the same question as the previous section, arriving from a different direction.

None of that is a reason not to pursue assessment or treatment. It is a reason to go in with accurate expectations, ask about the handover early, and not read a system-level delay as a personal one.

What should you actually bring to a titration appointment?

Two things: a record, and a short list of questions.

The record matters because memory of the last fortnight is not a reliable instrument — for anyone, and particularly not when the thing you are trying to remember is your own attention. A few notes each day on sleep, appetite, energy and what actually changed will tell your prescriber more than a well-meaning summary produced under time pressure in the room.

The questions worth having written down:

What are we trying to improve, and how will we both know if it has worked?
How long should I give this before it is fair to judge it?
Which effects should I report straight away, and which can wait until review?
What monitoring will I need, and how often?
Who prescribes once I'm stable — and is shared care agreed with my practice?
What happens if this one doesn't suit me? What's the next step?

That last one deserves asking out loud at the first appointment, not the third. Knowing that a plan B exists changes how a difficult fortnight feels. And if you have been experimenting with caffeine to smooth out the day, it is worth reading what the evidence actually says about coffee and stimulant timing before you take that question to your appointment — it is a better conversation with the two curves in front of you.

How Ecstasis helps

Ecstasis does not prescribe, recommend, or tell you whether your medication is working — those belong to your prescriber, and any app claiming otherwise is overreaching. What it does is make the record-keeping part survivable. Logging energy, sleep, appetite and what you actually got done is exactly the sort of task that falls apart when the effort of capture exceeds the motivation to capture, so it is built to take seconds rather than minutes: a few words of voice, a tap, done. Over a titration period that turns "I think the afternoons got worse, maybe?" into something you can show someone.

Ecstasis is in early development. Join the waitlist at ecstasis.app and we'll let you know the moment the beta opens. No pressure either way — if the only thing you take from this article is the list of questions above, that is a good outcome.

This is education, not medical advice

Everything here is general education about a process, not a diagnosis, a treatment plan, a dose, or a schedule. Nothing in this article should be used to start, stop, adjust or delay any medication — those decisions belong to a qualified prescriber who can see your history, your other conditions and your current health. If you are waiting for an assessment, struggling with side effects, or wondering whether treatment is right for you at all, the right next step is a conversation with a professional, not a blog. Talk to your GP or prescriber.

References

Brikell I, et al. ADHD medication discontinuation and persistence across the lifespan. The Lancet Psychiatry. 2024;11(1):16–26. PMID: 38035876. DOI: 10.1016/S2215-0366(23)00332-2.
Carucci S, Balia C, Gagliano A, et al; ADDUCE Consortium. Long term methylphenidate exposure and growth in children and adolescents with ADHD. Neuroscience & Biobehavioral Reviews. 2021;120:509–525. PMID: 33080250.
Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2018;5(9):727–738. PMID: 30097390. DOI: 10.1016/S2215-0366(18)30269-4.
Farhat LC, Lannes A, Del Giovane C, et al. Comparative cardiovascular safety of medications for attention-deficit/hyperactivity disorder. The Lancet Psychiatry. 2025;12(5):355–365. PMID: 40203844. DOI: 10.1016/S2215-0366(25)00062-8.
Gajria K, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder — a systematic literature review. Neuropsychiatric Disease and Treatment. 2014. PMID: 25187718. DOI: 10.2147/NDT.S65721.
National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline NG87. Published 14 March 2018, last updated 13 September 2019. https://www.nice.org.uk/guidance/ng87
NHS England. Patient choice guidance. https://www.england.nhs.uk/long-read/patient-choice-guidance/
NHS England. Report of the independent ADHD Taskforce. 2025. https://www.england.nhs.uk/publication/report-of-the-independent-adhd-taskforce/
Price A, Becker K, Ward JH, et al. Support for primary care prescribing for adult ADHD in England: national survey. British Journal of General Practice. 2024;74(748):e777–e783. PMID: 38621804. DOI: 10.3399/BJGP.2023.0595.
Zhang L, Li L, Andell P, et al. Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry. 2024;81(2):178–187. PMID: 37991787. DOI: 10.1001/jamapsychiatry.2023.4294.

Starting ADHD Medication in the UK: What Titration Actually Involves